The standard therapy for chordoma is excision Local

The standard therapy for chordoma is excision. Local recurrence, but not metastasis, is a major determinant of prognosis. Because local recurrence is related to initial surgical margin and intra-operative tumor cell contamination, achieving a safe margin is very important. Boriani [6] reported 153 cases of chordoma patients who underwent surgery. The recurrence and survival rates were 26.2% and 86.2%, respectively, for patients with safe margins; they were 78.4% and 58%, respectively, for those receiving intralesional resection. Others have reported recurrence rates of 43–85% [9–12]. Wide resection can significantly reduce the recurrence rate; however, it p2y inhibitor is often very difficult to achieve. Fuchs [13] reported 31 cases with wide resection, only one of whom relapsed. However, 22 of 31 patients in whom wide margins were not achieved relapsed. Yonemoto [14] reported a recurrence rate after intracapsular resection of 60%; no patients in whom wide resection was achieved relapsed. In our patient, wide excision of the iliac lesion was achieved and the patient made a good functional recovery and has had no recurrence. Boriani [6] reported adenosine triphosphate (ATP) patients who have undergone intralesional resection and have residual tumors can benefit from postoperative radiotherapy. Many recent studies [12,15,16] have reported that postoperative radiotherapy can relieve pain and prolong disease-free survival. Reported 5-year and 10-year survival rates are 45–87% and 28–71%, respectively. Some factors such as being male, younger age, smaller tumor, and early treatment may be associated with a good prognosis [1,6,9–14,17,18].
Conflict of interest statement
Ethical review committee statement
Acknowledgments